8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2017 / Randomized double-blind placebo-controlled trial
Seventy patients with non-alcoholic fatty liver disease were randomized to receive 1,200 mg daily of Chlorella vulgaris or placebo for 8 weeks. Weight reduction was significantly greater in the supplemented arm compared to placebo. Between-group differences in mean changes were significant for serum glucose and TNF-α after adjusting for baseline values and insulin (reported adjusted P-values: 0.014, 0.005, 0.014), but not for other measured outcomes.
Ebrahimi-Mameghani M, Sadeghi Z, Abbasalizad Farhangi M, et al. Clin Nutr, 2017. PMID 27475283
2017 / Comparative crossover trial
Researchers evaluated the effect of no mouthwash, a water mouthwash, and a menthol mouthwash on crisp aftertaste perception and appetite. In the appetite study with 36 subjects, the water mouthwash did not alter desire, liking, hunger, thirst, or ad libitum intake. In contrast, the menthol mouthwash significantly reduced crisp desire, liking, hunger, and thirst, and lowered ad libitum crisp intake by 29% over a 12-minute period.
Hutchings SC, Horner KM, Dible VA, et al. Appetite, 2017. PMID 27663531
2017 / Randomized controlled trial
A randomized, double-blind trial gave 44 overweight or obese adults either yeast beta-glucan (up to 954 mg daily) or placebo for six weeks. Compared to placebo, beta-glucan significantly reduced waist circumference (p = 0.037), blood pressure (p = 0.006), and IL-6 at week six (p = 0.005), while increasing IL-10 (p < 0.001). No significant differences appeared in lipid profiles, liver and kidney markers, or nutrient intake.
Mosikanon K, Arthan D, Kettawan A, et al. J Diet Suppl, 2017. PMID 27715351
2017 / Randomized controlled trial
In an 81-patient randomized trial of overweight and obese women with type 2 diabetes on a weight loss program, replacing diet beverages with water after lunch 5 times per week resulted in greater decreases in weight (-6.40 ± 2.42 kg vs -5.25 ± 1.60 kg; P = .006) and BMI (-2.49 ± 0.92 kg/m2 vs -2.06 ± 0.62 kg/m2; P = .006) over 24 weeks compared to continuing diet beverages. The water group also achieved significantly greater reductions in fasting plasma glucose, fasting insulin, HOMA-IR, and 2-hour postprandial glucose. However, no significant time × group interaction was found for waist circumference, lipid profiles, or HbA1c.
Madjd A, Taylor MA, Delavari A, et al. Diabetes Obes Metab, 2017. PMID 27748014
2017 / Randomized crossover trial
A randomized crossover trial in 30 healthy men compared mid-morning preloads sweetened with aspartame, monk fruit, stevia, or sucrose (65 g). Ad libitum lunch intake was higher after non-nutritive sweetener drinks than sucrose (P = 0.010), leading to full compensation and no difference in total daily energy intake (P = 0.831). Three-hour total area under the curve for glucose (P = 0.960) and insulin (P = 0.216) did not differ among the four beverages.
Tey SL, Salleh NB, Henry J, et al. Int J Obes (Lond), 2017. PMID 27956737
2017 / Double-blind, randomized, placebo-controlled parallel trial
In a double-blind trial, 53 overweight and mild hypercholesterolemic subjects consumed an 80 mL pouch containing 13.5 g of wolfberry extract (WBE) or placebo daily after a meal for 8 weeks. WBE supplementation resulted in a slight but significant decrease in erythrocyte superoxide dismutase activity and an increase in catalase activity. Endogenous DNA damage in lymphocytes, evaluated as the percentage of DNA in the tail via alkaline comet assay, significantly decreased with 8 weeks of WBE. In addition, the proportion of significantly deregulated mRNAs related to oxidative or inflammatory stress was considerably higher in the WBE group.
Lee YJ, Ahn Y, Kwon O, et al. J Agric Food Chem, 2017. PMID 28027641
2017 / Randomized controlled trial
Forty-nine nonhabitual breakfast-eating women were randomized for four weeks to either consume breakfast (at least 15% of daily energy requirement before 8:30 a.m.) or skip breakfast (no energy intake until after 11:30 a.m.). Participants assigned to eat breakfast consumed on average 266 ± 496 more calories per day (P < 0.01) and weighed 0.7 ± 0.8 kg more at the end of the intervention (p < 0.01). No caloric compensation was observed at subsequent meals, and there were no changes in self-reported hunger, satiety, or physical activity compensation.
LeCheminant GM, LeCheminant JD, Tucker LA, et al. Appetite, 2017. PMID 28063876
2017 / Randomized controlled trial
In a 6-month trial involving 77 overweight or obese adults with type 2 diabetes, participants received either Salba-chia or an oat bran control alongside a calorie-restricted regimen. Those receiving Salba-chia achieved greater weight loss (1.9 ± 0.5 kg vs. 0.3 ± 0.4 kg; P = 0.020) and greater waist circumference reductions (3.5 ± 0.7 cm vs. 1.1 ± 0.7 cm; P = 0.027). Salba-chia also produced superior decreases in C-reactive protein (P = 0.045) and increased adiponectin levels (P = 0.022).
Vuksan V, Jenkins AL, Brissette C, et al. Nutr Metab Cardiovasc Dis, 2017. PMID 28089080
2017 / Randomized controlled trial
A 12-week randomized trial assigned 60 overweight and mildly obese adults to consume 45 g daily of either red sorghum or white wheat flaked biscuits within an energy-restricted meal plan. Weight loss was equivalent between groups (P = 0.369), and no differences emerged for glucose, lipids, or inflammatory markers. Both groups showed improvements over time, but red sorghum provided no unique benefits.
Stefoska-Needham A, Beck EJ, Johnson SK, et al. J Am Coll Nutr, 2017. PMID 28135975
2017 / Randomized, placebo-controlled, double-blind parallel trial
A 16-week randomized, placebo-controlled, double-blind trial investigated daily oral supplementation with 1000 mg resveratrol (RSVhigh), 150 mg resveratrol, or placebo in 74 middle-aged men with metabolic syndrome. Resveratrol did not alter circulating hs-CRP, interleukin 6, soluble urokinase plasminogen activator receptor, or inflammatory gene expression in muscle and adipose tissues, and showed no effect on blood pressure, body composition, or glucose and lipid metabolism. However, RSVhigh treatment significantly increased total cholesterol (P < 0.002), LDL cholesterol (P < 0.006), and fructosamine (P < 0.013) compared with placebo.
Kjær TN, Ornstrup MJ, Poulsen MM, et al. J Clin Endocrinol Metab, 2017. PMID 28182820
2017 / Randomized controlled crossover trial
In a randomized trial involving 100 healthy participants, three monthly 5-day cycles of a fasting-mimicking diet reduced body weight, trunk fat, total body fat, blood pressure, and insulin-like growth factor 1. Crossover of the control group resulted in 71 participants finishing three cycles without serious adverse effects. A post hoc analysis revealed that improvements in blood pressure, fasting glucose, cholesterol, triglycerides, and C-reactive protein were greater in individuals initially at risk for disease.
Wei M, Brandhorst S, Shelehchi M, et al. Sci Transl Med, 2017. PMID 28202779
2017 / Double-blind, parallel, randomized placebo-controlled trial
A double-blind, parallel, randomized placebo-controlled trial examined the effects of eight weeks of daily supplementation with six capsules of fruit and vegetable juice concentrate or placebo in 56 overweight and obese adults aged ≥40 years. Following consumption of the juice concentrate, total cholesterol, LDL cholesterol, and plasma TNFα decreased and total lean mass increased, with no change in the placebo group. In participants with high baseline systemic inflammation (serum CRP ≥3.0 mg/mL, n = 16), these effects were greater, though plasma CRP remained unchanged. The concentrate also altered the expression of genes involved in lipogenesis, NF-κB, and AMPK signalling pathways, such as PMVK, ZFAND5, and CAB39.
Williams EJ, Baines KJ, Berthon BS, et al. Nutrients, 2017. PMID 28208713
2017 / Randomized controlled trial
In a multicenter randomized controlled trial, 218 nonobese adults aged 21-51 years followed 25% calorie restriction or ad libitum eating for two years. The calorie restriction group achieved an 11.9% ± 0.7% energy reduction, lowering weight (-7.6 ± 0.3 vs 0.4 ± 0.5 kg), fat mass (-5.4 ± 0.3 vs 0.5 ± 0.4 kg), and fat-free mass (-2.0 ± 0.2 vs -0.0 ± 0.2 kg). Fat-free mass as a percentage of total body weight was higher in the calorie restriction group than controls.
Das SK, Roberts SB, Bhapkar MV, et al. Am J Clin Nutr, 2017. PMID 28228420
2017 / Randomized, double-blind, placebo-controlled trial
Forty-two children aged 7-12 years with BMI >=85th percentile were randomized to receive 8 g/d of oligofructose-enriched inulin or maltodextrin placebo for 16 weeks. Compared with placebo, prebiotics led to significantly higher fullness (P = 0.04) and lower prospective food consumption (P = 0.03) at a week 16 breakfast buffet, and significantly reduced energy intake in 11- to 12-year-olds (P = 0.04) but not 7- to 10-year-olds. Fasting adiponectin (P = 0.04) and ghrelin (P = 0.03) significantly increased with prebiotics compared to placebo. Prebiotic supplementation showed a trend toward reducing BMI z score in intent-to-treat analysis (-3.4%; P = 0.09) and a significant -3.8% reduction in per-protocol analysis (P = 0.043).
Hume MP, Nicolucci AC, Reimer RA Am J Clin Nutr, 2017. PMID 28228425
2017 / Experimental psychology studies (5 studies)
Five studies investigated reactions to experts displaying exemplary behavior in the medical domain. Study 1 found people erroneously believe doctors maintain healthier habits than others, while Study 2 showed doctors advertise these habits. Study 3 demonstrated that individuals who are overweight or obese and concerned about their weight anticipate devaluation from, avoid, and feel less comfortable with fitness-focused doctors. Studies 4 and 5 examined communication strategies for physicians to highlight fitness without alienating weight-sensitive patients.
Howe LC, Monin B J Pers Soc Psychol, 2017. PMID 28240939
2017 / Randomized controlled trial
Thirty-eight adolescents with overweight or obesity receiving a weight-reducing intervention were randomized to receive additional advice and behavioral support to drink 8 cups of water per day or no water advice. At 6 months, self-reported water intake increased more in the water group (difference between groups, 1.6 cups per day [95% CI, 0.2 to 3.0]; P = .03). However, the 6-month change in body mass index z score did not differ between the water group and the control group (between-group difference, -0.0 [95% CI, -0.1 to 0.1]; P = .88). Despite intensive behavioral supports, few adolescents met the 8 cups per day target.
Wong JMW, Ebbeling CB, Robinson L, et al. JAMA Pediatr, 2017. PMID 28264082
2017 / Randomised, double-blind, placebo-controlled crossover trial
In a randomised, double-blind, placebo-controlled crossover trial, 30 subjects with obesity received 12 weeks of once-weekly subcutaneous semaglutide (dose-escalated to 1.0 mg) or placebo. Semaglutide led to a lower ad libitum energy intake during lunch (-1255 kJ; P < .0001), the evening meal (P = .0401), and snacks (P = .0034), producing a 24% reduction in total daily ad libitum energy intake (-3036 kJ; P < .0001). Semaglutide also improved fasting appetite suppression scores, reduced hunger, cravings, and preference for high-fat foods, and reduced mean body weight by 5.0 kg predominantly from fat mass, with no difference in lean-mass-adjusted resting metabolic rate.
Blundell J, Finlayson G, Axelsen M, et al. Diabetes Obes Metab, 2017. PMID 28266779
2017 / Prospective longitudinal follow-up of a randomized controlled trial
Researchers evaluated 39 nonobese adults at 12 and 24 months after finishing the 2-year CALERIE 2 trial (25% calorie restriction vs. ad libitum control). Following an initial mean weight loss of 9.0 ± 0.6 kg in the CR group, participants regained only 54% of that weight 2 years post-intervention. Weight, percentage of body fat, and fat mass remained significantly lower than baseline and significantly below the control group throughout follow-up (P < 0.05). The CR group also maintained higher levels of dietary restraint and avoidance of specific foods.
Marlatt KL, Redman LM, Burton JH, et al. Am J Clin Nutr, 2017. PMID 28275127
2017 / Randomized controlled trial
In a randomized controlled trial of 65 adults with overweight or obesity and cardiometabolic conditions, an ad libitum whole food plant-based diet was compared to usual care. At 6 months, mean BMI reduction was significantly greater in the diet group (difference: 3.9 kg m-2, 95% CI ±1, P < 0.0001). Total cholesterol reduction did not significantly differ between groups unless dropouts were excluded (difference: 0.56 mmol l-1, P = 0.05).
Wright N, Wilson L, Smith M, et al. Nutr Diabetes, 2017. PMID 28319109
2017 / Randomized controlled trial
In a randomized trial with 683 participants, only individuals assigned to the genetic advice arm received information regarding their FTO genotype status. At 6 months, FTO risk allele carriers in this group lost more weight (-2.28 kg, 95% CI: -3.06 to -1.48 vs. -1.99 kg, 95% CI: -2.19 to -0.19; P = 0.037) and more waist circumference (-4.34 cm vs. -1.99 cm; P = 0.048) than nonrisk carriers.
Celis-Morales C, Marsaux CF, Livingstone KM, et al. Am J Clin Nutr, 2017. PMID 28381478
2017 / Combined analysis of two randomized crossover trials
Data from two randomized crossover trials including 43 healthy adults were combined to assess interindividual differences in 24-hour ad libitum energy intake (EI) following sleep restriction (3.5-4 hours in bed/night) versus habitual sleep (7-9 hours in bed/night). Large interindividual variations in EI changes (ΔEI) were observed, ranging from -813 to 1437 kcal/d. Only protocol order was associated with ΔEI (β = -568 kcal/d, 95% CI -921 to -215 kcal/d; P = 0.002), with participants undergoing habitual sleep first demonstrating greater increases in EI during sleep restriction (P = 0.01).
McNeil J, St-Onge MP Obesity (Silver Spring), 2017. PMID 28401667
2017 / Randomized controlled explorative pilot trial
In an explorative trial, patients with type 2 diabetes were randomized to a 7-day fasting program (Buchinger method, ~300 kcal/day liquids) followed by dietary advice, or to usual care with dietary advice only. Of 46 enrolled participants, 32 completed the 4-month trial. After 4 months, mean weight decreased by 3.5 kg in the fasting group compared to 2.0 kg in controls (p=0.03), accompanied by a greater reduction in abdominal circumference (p=0.001). Fasting also resulted in a significant decrease in systolic (p=0.01) and diastolic (p=0.003) blood pressure, as well as increased quality of life (p=0.04), while improvements in HbA1c, insulin, and HOMA-index were non-significant.
Li C, Sadraie B, Steckhan N, et al. Exp Clin Endocrinol Diabetes, 2017. PMID 28407662
2017 / Randomized clinical trial
In a 1-year randomized clinical trial of 100 obese adults, alternate-day fasting produced weight loss similar to daily calorie restriction at month 6 (-6.8% vs -6.8%) and month 12 (-6.0% vs -5.3%) relative to control. Blood pressure, heart rate, triglycerides, fasting glucose, and insulin resistance did not differ significantly between intervention groups. However, dropout was highest with alternate-day fasting (38%), and low-density lipoprotein cholesterol was significantly elevated at month 12 (11.5 mg/dL).
Trepanowski JF, Kroeger CM, Barnosky A, et al. JAMA Intern Med, 2017. PMID 28459931
2017 / Randomized double-blind crossover trial
In a randomized crossover trial, 44 healthy women ingested placebo or potato extract standardized to 15 mg or 30 mg potato protease inhibitor II one hour before a 390 kcal breakfast. Both doses significantly lowered postprandial hunger, prospective consumption, and desire to eat while increasing fullness. The 15 mg dose significantly increased plasma cholecystokinin levels over three hours, with no significant differences observed in glucose or insulin.
Zhu Y, Lasrado JA, Hu J Food Funct, 2017. PMID 28485429